Last reviewed · How we verify
AZD6234
AZD6234 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes.
AZD6234 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes. Used for Relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), Relapsed or refractory follicular lymphoma.
At a glance
| Generic name | AZD6234 |
|---|---|
| Also known as | Dose 1 |
| Sponsor | AstraZeneca |
| Drug class | PI3K inhibitor |
| Target | PI3K delta and PI3K gamma |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
By inhibiting these enzymes, AZD6234 disrupts the PI3K/AKT signaling pathway, which is involved in the regulation of cell growth and survival. This can lead to the inhibition of cancer cell proliferation and survival, making it a potential therapeutic agent for various types of cancer.
Approved indications
- Relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
- Relapsed or refractory follicular lymphoma
Common side effects
- Diarrhea
- Nausea
- Vomiting
- Fatigue
- Cough
Key clinical trials
- A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity (PHASE1)
- Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist (PHASE2)
- A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD6234 After Repeat Dose Administration in Participants Who Are Overweight or Obese (PHASE1)
- A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone (PHASE2)
- This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / Overweight (PHASE2)
- A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and Overweight (PHASE1, PHASE2)
- A Study in Participants With Obesity or Overweight With at Least One Weight-related Comorbidity (PHASE2)
- Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD6234 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AZD6234 CI brief — competitive landscape report
- AZD6234 updates RSS · CI watch RSS
- AstraZeneca portfolio CI